Objectives The aim of this study was to compare ticagrelor monotherapy with dual-
antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting …

Dual antiplatelet therapy (DAPT) and subsequent P2Y12 inhibitor monotherapy, particularly
ticagrelor, is an emerging treatment strategy in patients undergoing percutaneous coronary …

Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …

Importance Among patients undergoing percutaneous coronary intervention (PCI), it
remains unclear whether the treatment efficacy of P2Y 12 inhibitor monotherapy after a short …

Aims Optimal timing and strategy of antiplatelet monotherapy after dual-antiplatelet therapy
(DAPT) consisting of aspirin and P2Y12 inhibitor for patients who underwent percutaneous …

Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …

Aims To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy
following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month …

Background: The optimal antiplatelet strategy in the second year after percutaneous
coronary intervention (PCI) remains unclear. Aims: We aimed to compare ticagrelor …

Abstract Background In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients
After Coronary Intervention), among high-risk patients undergoing percutaneous coronary …

Objectives The aim of this study was to assess the impact of age on the safety and efficacy of
ticagrelor monotherapy after percutaneous coronary intervention (PCI). Background As the …